Regeneron Pharmaceuticals, Inc. - Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Regeneron Pharmaceuticals, Inc. for the reporting period ending March 31, 2026. The document discloses the company's holdings in equity securities as required by the Securities and Exchange Commission.
Key Financial Metrics and Holdings
The filing details specific equity positions held by the company. It does not provide Regeneron's own revenue, profit, cash flow, or debt metrics. The disclosed holdings are as follows:
| Issuer | Security Class | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Adicet Bio, Inc. | Common Stock | 60,511 | $412,080 | Sole |
| Intellia Therapeutics, Inc. | Common Stock | 3,702,995 | $47,472,396 | Sole |
Material Changes
The filing text does not provide data for the prior comparable period; therefore, material changes in holdings or values cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is a statutory disclosure of investment holdings only.
Investor Verification Checklist
- Verify the total aggregate value of the disclosed positions ($47,884,476) against the company's total investment portfolio.
- Confirm the share counts and voting authority (Sole) for Adicet Bio, Inc. and Intellia Therapeutics, Inc.
- Note that this filing does not reflect Regeneron's operational financial performance (revenue, earnings, cash flow).
- Check subsequent filings for changes in these positions, as Form 13F is a quarterly snapshot.